2020
Frankenfeld CL , Menon N, Leslie TF. 2020. Racial disparities in colorectal cancer time-to-treatment and survival time for colorectal tumors and diagnosing hospital cancer-related diagnostic and treatment capabilities. Cancer Epidemiol 65:101684, https://doi.org/10.1016/j.canep.2020.101684 .
View Abstract
Publication: Manuscripts
Menon N, Leslie TF, Frankenfeld CL . 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; doi: 10.1016/j.puhe.2020.02.004 .
View Abstract
Publication: Manuscripts
2019
Hooda N , Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. J Oncol Pharmacy Prac (abstract 22), doi:10.1177/1078155219834495.
View Abstract
Publication: Manuscripts
Nordyke RJ, Reichert H , Bylsma LC , Jackson JJ, Gage SM, Fryzek J, Roy-Chaudhury P, Lithgow T. 2019. Costs attributable to arteriovenous fistula and arteriovenous graft placements in hemodialysis patients with Medicare coverage. Am J Nephrol 50(4):320-328; doi: 10.1159/000502507 .
View Abstract
Publication: Manuscripts
Malone DC, Dean R, Arjunji R, Jensen IS , Cyr PL , Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019 .
View Abstract
Publication: Manuscripts
Frankenfeld CL , Leslie TF. 2019. County-level socioeconomic factors and residential racial, Hispanic, poverty, and unemployment segregation associated with drug overdose deaths in the United States, 2010–2015. Ann Epidemiol 35(July):12–19; 10.1016/j.annepidem.2019.04.009 .
View Abstract
Publication: Manuscripts
Bylsma LC , Reichert H , Gage SM, Roy-Chaudhury P, Nordyke RJ, Fryzek J, Dahl SLM, Lithgow T, Lawson JH. 2019. Clinical outcomes of arteriovenous access in incident hemodialysis patients with Medicare coverage, 2012–2014. Am J Nephrol 49(2):156–164, doi: 10.1159/000495355 .
View Abstract
Publication: Manuscripts
2018
Jensen IS , Wu E, Sacks NC , Cyr PL , Chung KC. 2018. Budget impact analysis of using daunarubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits 11(7):380–386. PMID: 30647825 .
View Abstract
Publication: Manuscripts
Sacks NC , Sharma A, Cyr PL , Bertiger G, Dahdal DN, Brogadir S. Real-world evidence comparison of the efficacy and safety of different bowel preparation agents in patients with inflammatory bowel disease. Digestive and Disease Week, Washington DC, 2018.